B-intervention	0	10	Sequential
O	11	17	versus
B-control	18	28	concurrent
I-control	29	40	trastuzumab
O	41	43	in
O	44	52	adjuvant
O	53	65	chemotherapy
O	66	69	for
O	70	76	breast
O	77	83	cancer
O	83	84	.

O	85	90	NCCTG
O	91	92	(
O	92	97	North
O	98	105	Central
O	106	112	Cancer
O	113	122	Treatment
O	123	128	Group
O	128	129	)
O	130	135	N9831
O	136	138	is
O	139	142	the
O	143	147	only
O	148	158	randomized
O	159	164	phase
O	165	168	III
O	169	174	trial
O	175	185	evaluating
O	186	197	trastuzumab
O	198	203	added
O	204	216	sequentially
O	217	219	or
O	220	224	used
O	225	237	concurrently
O	238	242	with
O	243	255	chemotherapy
O	256	258	in
B-eligibility	259	267	resected
I-eligibility	268	274	stages
I-eligibility	275	276	I
I-eligibility	277	279	to
I-eligibility	280	283	III
I-eligibility	284	292	invasive
I-eligibility	293	298	human
I-eligibility	299	308	epidermal
I-eligibility	309	315	growth
I-eligibility	316	322	factor
I-eligibility	323	331	receptor
I-eligibility	332	333	2
I-eligibility	333	334	-
I-eligibility	334	342	positive
I-eligibility	343	349	breast
I-eligibility	350	356	cancer
O	356	357	.

O	358	366	Patients
O	367	375	received
B-intervention	376	387	doxorubicin
I-intervention	388	391	and
I-intervention	392	408	cyclophosphamide
O	409	414	every
O	415	416	3
O	417	422	weeks
O	423	426	for
O	427	431	four
O	432	438	cycles
O	438	439	,
O	440	448	followed
O	449	451	by
O	452	462	paclitaxel
O	463	469	weekly
O	470	473	for
O	474	476	12
O	477	482	weeks
O	483	484	(
O	484	487	arm
O	488	489	A
O	489	490	)
O	490	491	,
B-intervention	492	502	paclitaxel
I-intervention	503	507	plus
I-intervention	508	518	sequential
I-intervention	519	530	trastuzumab
O	531	537	weekly
O	538	541	for
O	542	544	52
O	545	550	weeks
O	551	552	(
O	552	555	arm
O	556	557	B
O	557	558	)
O	558	559	,
O	560	562	or
B-control	563	573	paclitaxel
I-control	574	578	plus
I-control	579	589	concurrent
I-control	590	601	trastuzumab
O	602	605	for
O	606	608	12
O	609	614	weeks
O	615	623	followed
O	624	626	by
O	627	638	trastuzumab
O	639	642	for
O	643	645	40
O	646	651	weeks
O	652	653	(
O	653	656	arm
O	657	658	C
O	658	659	)
O	659	660	.

O	661	664	The
O	665	672	primary
O	673	676	end
O	677	682	point
O	683	686	was
B-outcome-Measure	687	694	disease
I-outcome-Measure	694	695	-
I-outcome-Measure	695	699	free
I-outcome-Measure	700	708	survival
I-outcome-Measure	709	710	(
I-outcome-Measure	710	713	DFS
I-outcome-Measure	713	714	)
O	714	715	.

O	716	726	Comparison
O	727	729	of
O	730	733	arm
O	734	735	A
O	736	737	(
O	737	738	n
O	739	740	=
B-intervention-participants	741	742	1
I-intervention-participants	742	743	,
I-intervention-participants	743	746	087
O	746	747	)
O	748	751	and
O	752	755	arm
O	756	757	B
O	758	759	(
O	759	760	n
O	761	762	=
B-intervention-participants	763	764	1
I-intervention-participants	764	765	,
I-intervention-participants	765	768	097
O	768	769	)
O	769	770	,
O	771	775	with
O	776	777	6
O	777	778	-
O	778	782	year
O	783	789	median
O	790	796	follow
O	796	797	-
O	797	799	up
O	800	803	and
O	804	807	390
O	808	814	events
O	814	815	,
O	816	824	revealed
B-outcome	825	826	5
I-outcome	826	827	-
I-outcome	827	831	year
I-outcome	832	835	DFS
O	836	841	rates
O	842	844	of
B-iv-bin-percent	845	847	71
I-iv-bin-percent	847	848	.
I-iv-bin-percent	848	849	8
I-iv-bin-percent	849	850	%
O	851	854	and
B-iv-bin-percent	855	857	80
I-iv-bin-percent	857	858	.
I-iv-bin-percent	858	859	1
I-iv-bin-percent	859	860	%
O	860	861	,
O	862	874	respectively
O	874	875	.

B-outcome	876	879	DFS
O	880	883	was
O	884	897	significantly
O	898	907	increased
O	908	912	with
O	913	924	trastuzumab
O	925	930	added
O	931	943	sequentially
O	944	946	to
O	947	957	paclitaxel
O	958	959	(
O	959	962	log
O	962	963	-
O	963	967	rank
O	968	969	P
O	970	971	<
O	972	973	.
O	973	976	001
O	976	977	;
O	978	981	arm
O	982	983	B
O	983	984	/
O	984	987	arm
O	988	989	A
O	990	996	hazard
O	997	1002	ratio
O	1003	1004	[
O	1004	1006	HR
O	1006	1007	]
O	1007	1008	,
O	1009	1010	0
O	1010	1011	.
O	1011	1013	69
O	1013	1014	;
O	1015	1017	95
O	1017	1018	%
O	1019	1021	CI
O	1021	1022	,
O	1023	1024	0
O	1024	1025	.
O	1025	1027	57
O	1028	1030	to
O	1031	1032	0
O	1032	1033	.
O	1033	1035	85
O	1035	1036	)
O	1036	1037	.

O	1038	1048	Comparison
O	1049	1051	of
O	1052	1055	arm
O	1056	1057	B
O	1058	1059	(
O	1059	1060	n
O	1061	1062	=
B-intervention-participants	1063	1066	954
O	1066	1067	)
O	1068	1071	and
O	1072	1075	arm
O	1076	1077	C
O	1078	1079	(
O	1079	1080	n
O	1081	1082	=
B-control-participants	1083	1086	949
O	1086	1087	)
O	1087	1088	,
O	1089	1093	with
O	1094	1095	6
O	1095	1096	-
O	1096	1100	year
O	1101	1107	median
O	1108	1114	follow
O	1114	1115	-
O	1115	1117	up
O	1118	1121	and
O	1122	1125	313
O	1126	1132	events
O	1132	1133	,
O	1134	1142	revealed
B-outcome	1143	1144	5
I-outcome	1144	1145	-
I-outcome	1145	1149	year
I-outcome	1150	1153	DFS
O	1154	1159	rates
O	1160	1162	of
B-iv-bin-percent	1163	1165	80
I-iv-bin-percent	1165	1166	.
I-iv-bin-percent	1166	1167	1
I-iv-bin-percent	1167	1168	%
O	1169	1172	and
B-cv-bin-percent	1173	1175	84
I-cv-bin-percent	1175	1176	.
I-cv-bin-percent	1176	1177	4
I-cv-bin-percent	1177	1178	%
O	1178	1179	,
O	1180	1192	respectively
O	1192	1193	.

O	1194	1199	There
O	1200	1203	was
O	1204	1206	an
O	1207	1215	increase
O	1216	1218	in
B-outcome	1219	1222	DFS
O	1223	1227	with
O	1228	1238	concurrent
O	1239	1250	trastuzumab
O	1251	1254	and
O	1255	1265	paclitaxel
O	1266	1274	relative
O	1275	1277	to
O	1278	1288	sequential
O	1289	1303	administration
O	1304	1305	(
O	1305	1308	arm
O	1309	1310	C
O	1310	1311	/
O	1311	1314	arm
O	1315	1316	B
O	1317	1319	HR
O	1319	1320	,
O	1321	1322	0
O	1322	1323	.
O	1323	1325	77
O	1325	1326	;
O	1327	1329	99
O	1329	1330	.
O	1330	1331	9
O	1331	1332	%
O	1333	1335	CI
O	1335	1336	,
O	1337	1338	0
O	1338	1339	.
O	1339	1341	53
O	1342	1344	to
O	1345	1346	1
O	1346	1347	.
O	1347	1349	11
O	1349	1350	)
O	1350	1351	,
O	1352	1355	but
O	1356	1359	the
O	1360	1361	P
O	1362	1367	value
O	1368	1369	(
O	1369	1370	.
O	1370	1372	02
O	1372	1373	)
O	1374	1377	did
O	1378	1381	not
O	1382	1387	cross
O	1388	1391	the
O	1392	1404	prespecified
O	1405	1406	O
O	1406	1407	'
O	1407	1412	Brien
O	1412	1413	-
O	1413	1420	Fleming
O	1421	1429	boundary
O	1430	1431	(
O	1431	1432	.
O	1432	1437	00116
O	1437	1438	)
O	1439	1442	for
O	1443	1446	the
O	1447	1454	interim
O	1455	1463	analysis
O	1463	1464	.

B-outcome	1465	1468	DFS
O	1469	1472	was
O	1473	1486	significantly
O	1487	1495	improved
O	1496	1500	with
O	1501	1503	52
O	1504	1509	weeks
O	1510	1512	of
O	1513	1524	trastuzumab
O	1525	1530	added
O	1531	1533	to
O	1534	1542	adjuvant
O	1543	1555	chemotherapy
O	1555	1556	.

O	1557	1559	On
O	1560	1563	the
O	1564	1569	basis
O	1570	1572	of
O	1573	1574	a
O	1575	1583	positive
O	1584	1588	risk
O	1588	1589	-
O	1589	1596	benefit
O	1597	1602	ratio
O	1602	1603	,
O	1604	1606	we
O	1607	1616	recommend
O	1617	1621	that
O	1622	1633	trastuzumab
O	1634	1636	be
O	1637	1649	incorporated
O	1650	1654	into
O	1655	1656	a
O	1657	1667	concurrent
O	1668	1675	regimen
O	1676	1680	with
O	1681	1687	taxane
O	1688	1700	chemotherapy
O	1701	1703	as
O	1704	1706	an
O	1707	1716	important
O	1717	1725	standard
O	1725	1726	-
O	1726	1728	of
O	1728	1729	-
O	1729	1733	care
O	1734	1743	treatment
O	1744	1755	alternative
O	1756	1758	to
O	1759	1760	a
O	1761	1771	sequential
O	1772	1779	regimen
O	1779	1780	.
